We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Represents GE in Acquisition of Strategic Assets from Thermo Fisher Scientific

09 January 2014

WASHINGTON, D.C. 9 January 2014 – Hogan Lovells represented GE Healthcare in connection with its agreement to acquire Thermo Fisher Scientific’s HyClone™ cell culture media and sera, gene modulation and magnetic beads businesses for approximately US$1.06 billion. The businesses will become part of GE Healthcare's Life Sciences division. The deal was announced on 6 January, 2014.

Hogan Lovells Washington, D.C. partners Joseph Gilligan and Paul Manca led the multidisciplinary team advising GE Healthcare with assistance from Warren Gorrell (Co-CEO, Washington, D.C.) and other partners and counsel from the corporate, regulatory, intellectual property, tax, environmental, real estate, employment and employee benefits groups, including:  Christine Burke, Celine Crowson, Dan Davidson, Beth Peters, Randy Prebula, Audrey Reed, Scott Reisch, Anthony Ryan, Amit Saluja, Martha Steinman, T. Weymouth and Michael Williams.

Loading data